Evidence on Buprenorphine Dose Limits: A Review

Area of Science:

• Addiction Medicine
• Pharmacology
• Public Health

Background:

• Fentanyl overdose deaths are rising, increasing the importance of effective opioid use disorder (OUD) treatments.
• Buprenorphine is a vital medication for reducing OUD overdose mortality, contingent on sustained patient engagement in treatment.
• Current Food and Drug Administration (FDA) guidelines limit buprenorphine dosing, potentially hindering treatment efficacy.

Approach:

• This review examines patient-centered goals and clinical indicators for adequate buprenorphine dosing.
• It analyzes the historical regulation of buprenorphine dosage in the U.S.
• The review evaluates pharmacological and clinical data on buprenorphine doses up to 32 mg/d and assesses diversion concerns.

Key Points:

• Research consistently shows buprenorphine's benefits increase with dose, up to at least 32 mg/d.
• These benefits include reduced withdrawal, craving, opioid reward, and illicit use, alongside improved treatment retention.
• Diverted buprenorphine is often used to manage withdrawal and reduce illicit opioid use when access is restricted.

Conclusions:

• Current FDA buprenorphine dosing recommendations are outdated and potentially harmful given the fentanyl crisis.
• Updating the buprenorphine label to recommend doses up to 32 mg/d and removing the 16 mg/d target dose would enhance treatment effectiveness.
• Revised dosing guidelines have the potential to save lives by improving treatment outcomes for individuals with OUD.